Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

To join this study, you must be an adult aged 18 or over and have a confirmed diagnosis of advanced squamous non-small cell lung cancer that has spread. Importantly, your cancer must have continued to grow despite having received prior treatment with both a type of immunotherapy (anti-PD-1/PD-L1) and chemotherapy that contained platinum for your advanced cancer.

There are also some medical conditions that would prevent you from taking part, such as active and uncontrolled heart problems, severe lung conditions, or if you've already received a specific chemotherapy drug called docetaxel on its own or with other treatments. If you have HIV or Hepatitis B or C, you might still be able to join if your condition is well-managed with treatment and your viral levels are undetectable.

Minor side effects from previous cancer treatments must have mostly cleared up. The study team will review all your medical information to make sure it's safe and appropriate for you to participate.

If you join this study, you would receive one of the investigational (study) medicines or standard chemotherapy, as decided by the study team. You would receive these treatments at regular intervals, likely through an infusion (drip) in a hospital or clinic setting. There would be regular hospital visits for blood tests, physical examinations, and scans (like CT scans) to monitor your health and how the treatment is affecting the cancer.

While the exact schedule isn't detailed, clinical trials typically involve frequent visits at the beginning, becoming less frequent over time. You would also be asked about any side effects you experience. If your cancer gets worse, you might be offered 'rescue medications' to help. The total duration of your participation would depend on how your cancer responds and how you tolerate the treatment, but it could last for many months.